Q32 Bio names José Trevejo chief medical officer
Reuters2026/09/14 10:59- Q32 Bio named José Trevejo as chief medical officer.
- Trevejo was chief medical officer and head of clinical pipeline strategy at Enveda Therapeutics.
- Earlier roles include chief medical officer at Tarsus Pharmaceuticals, chief development officer at Rocket Pharmaceuticals, chief executive officer at SmartPharm Therapeutics.
- Ellie Hershberger appointed chief development officer.
- Hershberger previously served as chief development officer at Adagio Therapeutics, now Invivyd, leading its lead monoclonal antibody into Phase 3.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Historical data shows that a single rate hike is not enough to end a bull market; a full tightening cycle is the real threat.
Since 1945, the S&P 500 has experienced 12 bear markets with declines of over 20% and 4 deep corrections ranging from 18% to 20%. Among them, six occurred directly after interest rate hikes that triggered economic recessions, while two other cases had no relation to either rate hikes or recessions. Goldman Sachs believes that the market has already priced in multiple rate hike expectations; Morgan Stanley warns that rising yields could trigger a market correction; JPMorgan is more focused on oil prices and corporate earnings.
Rogers Communications Upgraded to Buy at Desjardins
Focus Graphite Establishes CA$2 Million Revolving Credit Facility With CIBC
Crypto prices
More
